Bachem Holding, an innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides, has raised CHF 583.5 million through an accelerated bookbuilding process by issuing 750,000 new shares at a placement price of CHF 778 per
Tags :Matthias Staehelin
Anjarium Biosciences, a Swiss biotech company, recently closed a CHF 55.5 million (USD 61 million) Series A financing round, co-led by Gimv and Abingworth. The fundraising also saw significant participation from Omega Funds, Pfizer Ventures and surveyor
Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals. The acquisition broadens Novaremed’s existing pipeline by adding both
EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in
Kuros Biosciences, a bone graft technologies company, has entered into a royalty purchase agreement with Xoma Corporation, under which Xoma has purchased a proportion of the potential future pre-commercial milestone payments and all the potential
Vischer has acted as legal counsel to TargImmune Therapeutics, a private Swiss-based biotechnology firm, on the closing of its 2021 financing round, raising CHF 17.7 million. The Vischer legal team was led by Matthias Staehelin (pictured) with
Novartis has signed a collaboration agreement and option to acquire Cellerys, a Zurich-based start-up that is researching a therapy to combat multiple sclerosis (MS). This therapy has the potential to delay the progression of the
Swiss Nuclides, a developer of novel radionuclide Pet tracers for the precision diagnostics, has closed the first tranche of its series A financing round, raising CHF 2.6 million from private investors. Vischer has been acting as
Oculis has closed an oversubscribed USD 57m Series C financing round. It was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay
Drägerwerk AG & Co. KGaA, an international operator in the fields of medical and safety technology, has acquired a majority stake in the Swiss-based start-up medical technology company STIMIT. VISCHER advised Stimit and the
